Arrowhead Preps Phase I siRNA Drug Data for Publication, Raises $3.2M in Private Placement

According to Arrowhead President and CEO Christopher Anzalone, the data are expected to bolster the company's efforts to either divest or find a partner for Calando — a longstanding corporate goal — but he said that specific details about the clinical results were not yet being disclosed.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.